secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0000014272-24-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol Myers Q4 rev up 1% to $11.5B; Non-GAAP EPS $1.70; FY rev $45.0B; 2024 EPS guide $7.10-$7.40
--------------------------------------------------------------------------------

- Fourth quarter revenues $11.5B (+1% YoY); GAAP EPS $0.87, Non-GAAP EPS $1.70.
- Full-year revenues $45.0B (-2% YoY); GAAP EPS $3.86, Non-GAAP EPS $7.51.
- In-line & new product portfolio revenues: +9% in Q4, +7% in FY to $37.9B.
- 2024 guidance: revenue growth low single-digits; Non-GAAP EPS $7.10-$7.40 (excl. pending acquisitions).
- Pipeline: FDA approval of Augtyro; Breyanzi sBLAs accepted; completed Mirati purchase, pending Karuna & RayzeBio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000020/0000014272-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000020/bmy-20240202.htm
  HTML page:      https://secwatch.observer/filing/0000014272-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer